Author: Early Investing

Early Investing’s mission is to help its readers find the most promising investment opportunities outside the stock market. Our research is focused on two areas in particular: private startups and cryptocurrencies. We provide both educational material and recommendations on specific investments. With more than 140,000 readers and 40,000 subscribers, Early Investing is a leading destination for guidance in the alternative investment space.

Subscribe to Early's feed.

Premium

Crypto Monitor: Fidelity Ready to Launch Crypto Service; Bittrex Exits New York

Fidelity is mere weeks from launching its crypto trading service for institutional investors. But Binance, Bittrex and Bitfinex aren’t having as good of a week.

Premium

Cannabis Report: Canopy Growth’s Acreage Deal Meets Resistance; New Jersey Gets Petty

By Early Investing on May 9, 2019

Canopy Growth’s deal to buy Acreage Holdings has hit a snag, and New Jersey is mired in petty politics.

Mailbag: The Best Startup Investment Deal Terms and the Best Kind of Startup

By Early Investing on May 5, 2019

This week, the Early Investing team explains its favorite kind of startup and the best startup investment deal terms.

Mailbag: How to Avoid Startup Investing Mistakes, Why the Government Doesn’t Get Crypto

By Early Investing on April 28, 2019

This week, the Early Investing team tells readers how to avoid common startup investing mistakes and why the government doesn’t really “get” crypto.
Premium

Crypto Monitor: Binance Launches Decentralized Exchange, Altcoins Build Value

By Early Investing on April 26, 2019

This week, Binance launched its decentralized exchange ahead of schedule and altcoins have continued their rally. And a thief reminded us of the importance of secure passwords.
Premium

Cannabis Report: Canopy Growth Thinks Ahead While U.S. Cannabis Research Falls Behind

By Early Investing on April 25, 2019

This week in weed, an American cannabis stock makes its Nasdaq debut, Canopy Growth thinks ahead and the U.S. misses the boat on medical marijuana.
Premium

Arbit Poll: To Use or Not to Use Big Bank Cryptos

By Early Investing on April 22, 2019

Our last poll results show an intriguing divide among First Stage Investor members. To use or not to use big bank crypto coins?

Mailbag: What Startup Accelerators Do and Why Consumers Leave the Marijuana Black Market

By Early Investing on April 21, 2019

The Early Investing team answers questions about what startup accelerators do and why weed users leave the black market.

Mailbag: Understanding Resistance Levels and Foreign Stock Portfolio Allocation

By Early Investing on April 14, 2019

This week, the Early Investing Mailbag is tackling resistance levels and foreign stock allocation.
Premium

Crypto Monitor: Litecoin Blazes Ahead, SEC Issues Token Guidance

By Early Investing on April 12, 2019

This week in the crypto world, litecoin is on a tear and the SEC is finally offering guidance on tokens.
Premium

Cannabis Report: The Lowdown on Lighting and Cannabis Research

By Early Investing on April 11, 2019

The Early Investing team learned a lot at the Cannabis Science Conference. This week, we’re focusing on two takeaways: lighting and research.

Mailbag: The Logic Behind Lyft’s IPO, Investing in Precious Metals

By Early Investing on April 7, 2019

In this week’s Mailbag, Andy tackles the logic behind Lyft’s IPO and Adam talks precious metals.

Mailbag: Startup Growth vs. Profits, Exploring OTC Markets

By Early Investing on March 31, 2019

In this week’s Mailbag, Early Investing tackles growth over profits and OTC trading.
Premium

Crypto Monitor: Altcoins Ramp Up, Bakkt Faces Delays

By Early Investing on March 29, 2019

This week, altcoins are getting a boost, Bakkt is getting delayed and CNBC is getting it wrong.
Premium

Cannabis Report: Demand the Government Do Better

By Early Investing on March 28, 2019

The nascent cannabis industry is very reliant on the government in order to succeed. So the government needs to get it together.
Premium

Behind the Pick: Phoenix PharmaLabs

By Early Investing on March 25, 2019

First Stage Investor Co-Founder Andy Gordon takes a deeper dive into why he likes Phoenix Pharma Labs so much and the "X" factor that put them over the top.